Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV)

阅读量：

作者：

C Wheeler，A Khurshid，J Ibrahim，A Elias，P Mauch，K Ault，J Antin

展开

摘要：

Secondary malignancies, particularly myelodysplasia (MDS), are serious events following high dose therapy with autologous stem cell support. We observed a higher frequency of secondary malignancies in patients with Hodgkin''s disease (HD) than in patients with non-Hodgkin''s lymphoma (NHL) undergoing high dose therapy with the same non-TBI conditioning regimen. Three hundred patients with Hodgkin''s disease (HD) and non-Hodgkin''s lymphoma (NHL) were treated with Cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994. Median follow up of survivors is 3.9 years. Five-year survival is 51 % for HD and 48 % for NHL. Eleven patients developed second malignancies (9/150 treated for HD vs. 2/150 treated for NHL) a median of 2.4 years from transplantation and 5.2 years from initial diagnosis. Six patients had myelodysplasia or acute leukemia (MDS/AML) and 5 had lymphomas or solid tumors. Actuarial risk of MDS/AML at five years for patients transplanted for non-Hodgkin''s lymphoma is 3 % (95 % CI 0.69.6%). HD patients had significantly different pretreatment characteristics than patients with NHL. A Cox model showed that greater number of prior relapses and prior radiation therapy were significant risk factors for the development of MDS/AML. These data suggest that C V is associated with a lower risk of secondary MDS/AML than TBI containing regimens and that much of the risk is associated with the pre-transplantation therapy. The use of autotransplantation early in the course of therapy for relapsed lymphoma might prevent some cases of MDS/AML.

展开

关键词：

incidence post transplant myelodysplasia MDS acute leukemia non-Hodgkin's lymphoma Hodgkin's disease autologous transplantation Cyclophosphamide carmustine etoposide